Log In
BCIQ
Print this Print this
 

dipraglurant-ER

  Manage Alerts
Collapse Summary General Information
Company Addex Therapeutics Ltd.
DescriptionExtended release formulation of dipraglurant, a negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5)
Molecular Target Metabotropic glutamate receptor subtype 5 (mGluR5) (GRM5)
Mechanism of ActionMetabotropic glutamate receptor subtype 5 (mGluR5) modulator
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHyperkinetic movement disorder
Indication DetailsTreat cervical dystonia; Treat non-Parkinsonian dystonia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/19/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today